DNAM-1/CD226 Antibody (102511) [Unconjugated]

Human peripheral blood mononuclear cells (PBMCs) gated on CD3- cells were stained with Mouse Anti-Human NCAM‑1/CD56 APC‑conjugated Monoclonal Antibody (Catalog # FAB2408A) and either (A) Mouse Anti-Human DNAM-1/CD226 Monoclonal Antibody (Catalog # MAB666) or (B) Mouse IgG1 Isotype Control (Catalog # MAB002) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B).

Human peripheral blood mononuclear cells (PBMCs) gated on CD3- cells were stained with Mouse Anti-Human NCAM‑1/CD56 APC‑conjugated Monoclonal Antibody (Catalog # FAB2408A) and either (A) Mouse Anti-Human DNAM-1/CD226 Monoclonal Antibody (Catalog # MAB666) or (B) Mouse IgG1 Isotype Control (Catalog # MAB002) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B).

In a functional ELISA, Human DNAM-1/CD226 Antibody (Catalog # MAB666) blocks the binding of Recombinant Human DNAM-1/CD226 Fc Chimera (666-DN) to Biotinylated Recombinant Human CD155/PVR Fc Chimera Avi-tag (AVI9174). The Neutralization Dose (ND50) for this effect is typically 0.300-6.00 µg/mL.

• Reactivity: Hu
• Applications: WB, Flow, B/N, CyTOF-ready
• Clone: 102511
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

DNAM-1/CD226 Antibody (102511) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human DNAM-1/CD226
  Glu19-Asn247 (predicted)
  Accession # Q15762
• Specificity: Detects human DNAM-1/CD226 in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CD226
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Neutralization
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for DNAM-1/CD226 Antibody (102511) [Unconjugated]

• CD226 antigenplatelet and T cell activation antigen 1
• CD226 molecule
• CD226
• DNAM1
• DNAM-1
• DNAM1adhesion glycoprotein
• DNAM-1DNAX accessory molecule-1
• DNAX accessory molecule 1
• PTA1
• T lineage-specific activation antigen 1 antigen
• TLiSA1

Background

DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily (1). Mature human DNAM-1 contains a 236 amino acid (aa) extracellular domain (ECD) with two Ig-like C2-set domains and a 61 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, human DNAM-1 shares 50% and 52% aa sequence identity with mouse and rat DNAM-1, respectively. DNAM-1 is expressed on multiple lymphoid and myeloid cell types and interacts with CD155/PVR and Nectin-2/CD112 (3, 4). Ligation of DNAM-1 promotes the activation of NK cells, CD8⁺ T cells, and mast cells (2‑6), dendritic cell maturation, megakaryocyte and activated platelet adhesion to vascular endothelial cells, and monocyte extravasation; it inhibits the formation of osteoclasts (7‑10). Platelet-endothelium interactions mediated by DNAM-1 enable the metastasis of tumor cells to the lung (11). In activated, but not in resting NK, T, and mast cells, the cis association of DNAM-1 with CD18 contributes to the tyrosine and serine phosphorylation of DNAM-1 during activation (6, 9, 12‑14).

1. Fuchs, A. and M. Colonna (2006) Semin. Cancer Biol. 16:359.
2. Shibuya, A. et al. (1996) Immunity 4:573.
3. Bottino, C. et al. (2003) J. Exp. Med. 198:557.
4. Tahara-Hanaoka, S. et al. (2004) Int. Immunol. 16:533.
5. Dardalhon, V. et al. (2005) J. Immunol. 175:1558.
6. Bachelet, I. et al. (2006) J. Biol. Chem. 281:27190.
7. Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
8. Kakehi, S. et al. (2007) Mol. Cell. Biochem. 301:209.
9. Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
10. Tahara-Hanaoka, S. et al. (2006) Blood 107:1491.
11. Morimoto, K. et al. (2007) Oncogene July 16 epub.
12. Shibuya, K. et al. (1999) Immunity 11:615.
13. Shibuya, K. et al. (2003) J. Exp. Med. 198:1829.
14. Shibuya, A. et al. (1998) J. Immunol. 166:1671.

Show all background references

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for DNAM-1/CD226 Antibody (MAB666)(11)

Publications using MAB666

• S Sen Santar, DJ Lee,  Crespo, JJ Hu, C Walker, X Ma, Y Zhang, S Chowdhury, KF Meza-Sosa, M Lewandrows, H Zhang, M Rowe, A McClelland, H Wu, C Junqueira, J Lieberman The NK�cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells Nature, 2023-04-05;616(7956):348-356. 2023-04-05 [PMID: 37020026] (Neutralization, Human)
• A Chashchina, M Märklin, C Hinterleit, HR Salih, JS Heitmann, B Klimovich DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis Scientific Reports, 2021-09-09;11(1):18012. 2021-09-09 [PMID: 34504191] (Flow Cytometry, Human)
• Frank Cichocki, Ryan Bjordahl, Svetlana Gaidarova, Sajid Mahmood, Ramzey Abujarour, Hongbo Wang et al. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy Science Translational Medicine 2020-11-04 [PMID: 33148626] (Neutralization, Human)
• Elaine Y.L. Leung, Darren P. Ennis, Philippa R. Kennedy, Christopher Hansell, Suzanne Dowson, Malcolm Farquharson et al. NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer Molecular Therapy - Oncolytics 2020-03-27 [PMID: 32195317]
• DP Muñoz, SM Yannone, A Daemen, Y Sun, F Vakar-Lope, M Kawahara, AM Freund, F Rodier, JD Wu, PY Desprez, DH Raulet, PS Nelson, LJ van 't Vee, J Campisi, JP Coppé Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging JCI Insight, 2019-06-11;5(0):. 6/11/2019 [PMID: 31184599]
• M Najar, M Fayyad-Kaz, N Meuleman, D Bron, H Fayyad-Kaz, L Lagneaux Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation J Cell Commun Signal, 2018-01-19;0(0):. 2018-01-19 [PMID: 29350342] (Neutralization, Human)
• S López-Cobo, N Pieper, C Campos-Sil, EM García-Cue, HT Reyburn, A Paschen, M Valés-Góme Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors Oncoimmunology, 2017-11-06;7(2):e1392426. 2017-11-06 [PMID: 29308322] (Bioassay, Human)
• JL Espinoza, LQ Trung, PT Inaoka, K Yamada, DT An, S Mizuno, S Nakao, A Takami The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans Oxid Med Cell Longev, 2017-05-04;2017(0):6781872. 2017-05-04 [PMID: 28546852] (Flow Cytometry, Human)
• Davis Z, Sowrirajan B, Cogswell A, Ward J, Planelles V, Barker E CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells. AIDS Res Hum Retroviruses, 2016-07-20;33(2):93-100. 2016-07-20 [PMID: 27296670] (Neutralization, Human)
• Huijskens M, Walczak M, Sarkar S, Atrafi F, Senden-Gijsbers B, Tilanus M, Bos G, Wieten L, Germeraad W Ascorbic acid promotes proliferation of natural killer cell populations in culture systems applicable for natural killer cell therapy. Cytotherapy, 2015-03-05;17(5):613-20. 2015-03-05 [PMID: 25747742] (Flow Cytometry, Human)
• Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, Gregori S Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur. J. Immunol., 2011-05-13;41(6):1652-62. 2011-05-13 [PMID: 21469116] (Flow Cytometry, Human)

Review for DNAM-1/CD226 Antibody (MAB666) (1)

Average Rating: 5

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Verified Customer WB Human 10/24/2021

Summary

• Application: Western Blot
• Sample Tested: Mesenchymal stromal cells
• Species: Human
• Lot: 102511

Comments

• Comments: primary antibody dilution was 1:1000, secondary 1:4000

Bioinformatics

• Gene Symbol: CD226
• Uniprot:
  • Q15762()